Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.

نویسندگان

  • Giovanni Fabbrini
  • Piero Barbanti
  • Cinzia Aurilia
  • Caterina Pauletti
  • Giuseppe Meco
چکیده

The aim of our study was to investigate the efficacy of pramipexole in advanced parkinsonian patients by means of an acute stimulation test. We studied the motor effects of pramipexole in fluctuating parkinsonian patients by comparing the response to acute levodopa with the response to levodopa + pramipexole. The adjunct of pramipexole to levodopa increased the time spent on from 136 +/- 22.3 to 186 +/- 20.6 minutes (p<0.01), while it did not change the latency to on, the magnitude of the motor improvement, or the duration and severity of dyskinesias. The main effect of pramipexole in fluctuating parkinsonian patients is an increased duration of the on phase.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.

OBJECTIVE The long-term use of levodopa to treat Parkinson's disease (PD) is often limited by the development of motor complications (e.g., levodopa-induced dyskinesia, LID). We hypothesized that a non-ergot dopamine agonist with strong affinity for D3) dopamine receptors (pramipexole) may improve LID in patients taking an ergot D1/D2 dopamine agonist. METHODS Patients with PD and LID being t...

متن کامل

Role of pramipexole in the management of Parkinson's disease.

The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease and for the treatment of moderate-to-severe primary restless legs syndrome. A new extended-release formulation of pramipexole has now also been launched in Europe and the US to improve ease of use, compliance and provide a more continuous therapeutic ef...

متن کامل

Current and emerging treatments in Parkinson's disease.

INTRODUCTION Parkinson's disease is one of the commonest neurodegenerative diseases of the elderly. The discovery of dopamine deficiency from the degeneration of substantia nigra neurons revolutionised treatment in the early 70's. METHOD This review is based on Medline search with Keywords (Parkinson's disease, treatment, therapy, surgery). RESULTS Levodopa remains the gold standard of medi...

متن کامل

Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease.

OBJECTIVE To study the frequency and severity of acute orthostatic hypotension (OH) in patients with Parkinson's disease who are starting dopamine agonist therapy. PATIENTS AND METHODS In the context of an outpatient clinical practice, 29 consecutive patients with Parkinson's disease who were starting dopamine agonist therapy were brought into the clinic for their first dose of agonist. After...

متن کامل

Testosterone level and the effect of levodopa and agonists in early Parkinson disease: results from the INSPECT cohort

BACKGROUND To determine if testosterone levels are influenced by dopaminergic therapy in Parkinson disease (PD) patients. Testosterone level has been reported to be low in patients with PD and other neurodegenerative diseases. In this study, we sought to determine whether dopaminergic therapy (i.e. levodopa and dopamine agonist) influenced testosterone levels. We used a cohort of consecutive ma...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Functional neurology

دوره 17 4  شماره 

صفحات  -

تاریخ انتشار 2002